drugset / Trial / NCT05689645
F573 for Injection for the Treatment of Liver Injury/Failure
RandomizedParallel-groupTriple-blindTreatment
Summary
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
Timeline
- Start
- 2023-03-24
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F573 | Unknown | 0.5 mg/kg | Intramuscular |
| Subject | F573 | Unknown | 1 mg/kg | Intramuscular |
| Subject | F573 | Unknown | 2 mg/kg | Intramuscular |